Gotowa bibliografia na temat „Anticancer drugs”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Anticancer drugs”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Anticancer drugs"
D, Subba Reddy, Prasanthi G, Amruth Raj S, Hari Krishna T, Sowjanya K i Shantha Kumari K. "EVALUATION OF ANTICANCER GENERIC DRUGS AND BRANDED DRUGS". Indian Research Journal of Pharmacy and Science 5, nr 1 (marzec 2018): 1378–91. http://dx.doi.org/10.21276/irjps.2018.5.1.16.
Pełny tekst źródłaReese, David M. "Anticancer drugs". Nature 378, nr 6557 (grudzień 1995): 532. http://dx.doi.org/10.1038/378532c0.
Pełny tekst źródłaKutty, Dr A. V. M. "Usefulness of Phytochemicals as Anticancer Drugs". JOURNAL OF CLINICAL AND BIOMEDICAL SCIENCES 16, nr 1 (19.03.2019): 1–2. http://dx.doi.org/10.58739/jcbs/v09i1.7.
Pełny tekst źródłaAtkins, Joshua H., i Leland J. Gershell. "Selective anticancer drugs". Nature Reviews Drug Discovery 1, nr 7 (lipiec 2002): 491–92. http://dx.doi.org/10.1038/nrd842.
Pełny tekst źródłaAtkins, Joshua H., i Leland J. Gershell. "Selective anticancer drugs". Nature Reviews Cancer 2, nr 9 (wrzesień 2002): 645–46. http://dx.doi.org/10.1038/nrc900.
Pełny tekst źródłaBibby, M. C. "Combretastatin anticancer drugs". Drugs of the Future 27, nr 5 (2002): 475. http://dx.doi.org/10.1358/dof.2002.027.05.668645.
Pełny tekst źródłaMeegan, Mary J., i Niamh M. O’Boyle. "Special Issue “Anticancer Drugs”". Pharmaceuticals 12, nr 3 (16.09.2019): 134. http://dx.doi.org/10.3390/ph12030134.
Pełny tekst źródłaCiarimboli, Giuliano. "Anticancer Platinum Drugs Update". Biomolecules 11, nr 11 (4.11.2021): 1637. http://dx.doi.org/10.3390/biom11111637.
Pełny tekst źródłaZhang, Jason Y. "Apoptosis-based anticancer drugs". Nature Reviews Drug Discovery 1, nr 2 (luty 2002): 101–2. http://dx.doi.org/10.1038/nrd742.
Pełny tekst źródłaBlagosklonny, Mikhail V. "Teratogens as Anticancer Drugs". Cell Cycle 4, nr 11 (22.08.2005): 1518–21. http://dx.doi.org/10.4161/cc.4.11.2208.
Pełny tekst źródłaRozprawy doktorskie na temat "Anticancer drugs"
Apps, MIchael Garry. "Platinum anticancer drugs and drug delivery systems". Thesis, The University of Sydney, 2015. http://hdl.handle.net/2123/14409.
Pełny tekst źródłaKozlowska, Hanna. "Interaction of dexrazoxane with anticancer drugs". Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1998. http://www.collectionscanada.ca/obj/s4/f2/dsk2/tape17/PQDD_0001/MQ32158.pdf.
Pełny tekst źródłaTao, Zhimin. "Analysis of cytotoxicity of anticancer drugs". Related electronic resource:, 2007. http://proquest.umi.com/pqdweb?did=1407688361&sid=4&Fmt=2&clientId=3739&RQT=309&VName=PQD.
Pełny tekst źródłaLiu, Tong. "The synthesis of novel anticancer drugs". Thesis, University of Glasgow, 2003. http://theses.gla.ac.uk/4464/.
Pełny tekst źródłaSong, Di. "Bladder tissue pharmacokinetics of anticancer drugs /". The Ohio State University, 1996. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487940308433249.
Pełny tekst źródłaRatcliffe, Andrew J. "Synthesis of non-mutagenic anticancer drugs". Thesis, University of Bath, 1987. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.378598.
Pełny tekst źródłaPettersson, Hanna Ilse. "Quinolinequinones as anticancer agents". Thesis, University of Exeter, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.249038.
Pełny tekst źródłaWang, Shining. "DRUG DEVELOPMENT OF TARGETED ANTICANCER DRUGS BASED ON PK/PD INVESTIGATIONS". Diss., Temple University Libraries, 2008. http://cdm16002.contentdm.oclc.org/cdm/ref/collection/p245801coll10/id/2535.
Pełny tekst źródłaPh.D.
EGFR inhibitors, such as gefitinib, are examples of targeted anticancer drugs whose drug sensitivity is related to gene mutations that adds a pharmacogenetic [PG] dimension to any pharmacokinetic [PK] and pharmacodynamic [PD] analysis. The goal of this project was to characterize the PK/PD properties of gefitinib in tumors and then apply these results to design rational drug design regimens, and provide a foundation for future studies with EGFR inhibitors. Progressions of in vitro and in vivo studies were completed to understand the PK and PD behavior of gefitinib. In vitro cytotoxicity assays were first conducted to confirm the gefitinib sensitivity differences in a pair of human glioblastoma cell lines, LN229-wild-type EGFR and LN229-EGFRvIII mutant, an EGFR inhibitor-sensitizing mutation. Subsequent in vitro PD studies identified phosphorylated-ERK1/2 (pERK) as a common PD marker for both cell lines. To describe the most salient features of drug disposition and dynamics in the tumor, groups of mice bearing either subcutaneous LN229-wild-type EGFR or LN229-EGFRvIII mutant tumors were administered gefitinib at doses of 10 mg/kg intravenously (IV), 50 mg/kg intraarterially (IA) and 150 mg/kg orally (PO). In each group, gefitinib plasma and tumor concentrations were quantitated, as were tumoral pERK. Hybrid physiologically-based PK/PD models were developed for each tumor type, which consisted of a forcing function describing the plasma drug concentration-profile, a tumor compartment depicting drug disposition in the tumor, and a mechanistic target-response PD model characterizing pERK in the tumor. Gefitinib showed analogous PK properties in each tumor type, yet different PD characteristics consistent with the EGFR status of the tumors. Using the PK/PD model for each tumor type, simulations were done to define multiple-dose regimens for gefitinib that yielded equivalent PD profiles of pERK in each tumor type. Based on the designed PK/PD equivalent dosing regimens for each tumor type, gefitinib 150 mg/kg PO qd × 15 days and 65 mg/kg PO qd × 15 days multiple-dose studies were conducted in wild-type EGFR and EGFRvIII mutant tumor groups, respectively. In each tumor group, gefitinib plasma and tumor concentrations were measured on both day 1 and day 15, as were tumoral amounts of pERK. Different from single-dose model simulations, gefitinib showed nonlinear PK property in the wild-type tumor due to the down-regulation of membrane transporter ABCG2. Moreover, acquired resistance of tumoral pERK inhibition was observed in both tumor types. Nevertheless, gefitinib had an analogous growth suppression action in both tumor groups, supporting the equivalent PD dosing strategy. Overall, single-dose gefitinib PK/PD investigations in a pair of genetically distinct glioblastomas facilitated the development of hybrid physiologically-based PK/PD models for each tumor type, and further introduced a novel concept of PK/PD equivalent dosing regimens which could be applied in novel drug development paradigms. Preliminary multiple-dose gefitinib studies revealed more complex PK/PD characteristics that needed to be further explored.
Temple University--Theses
Leczkowska, Anna. "Non-covalent DNA-binding ruthenium anticancer drugs". Thesis, University of Birmingham, 2011. http://etheses.bham.ac.uk//id/eprint/1695/.
Pełny tekst źródłaYarema, Kevin J. (Kevin Jon). "Cellular responses to platinum-based anticancer drugs". Thesis, Massachusetts Institute of Technology, 1994. http://hdl.handle.net/1721.1/33495.
Pełny tekst źródłaKsiążki na temat "Anticancer drugs"
1938-, Pratt William B., i Pratt William B. 1938-, red. The anticancer drugs. Wyd. 2. New York: Oxford University Press, 1994.
Znajdź pełny tekst źródłaGarth, Powis, red. Anticancer drugs: Reactive metabolism and drug interactions. Oxford, England: Pergamon Press, 1994.
Znajdź pełny tekst źródłaAvendaño, Carmen. Medicinal chemistry of anticancer drugs. Amsterdam: Elsevier, 2008.
Znajdź pełny tekst źródłaConvention, United States Pharmacopeial. Fact sheets on anticancer drugs. [Washington, D.C.?]: National Cancer Institute [distributor], 1994.
Znajdź pełny tekst źródłaNational Cancer Institute (U.S.), red. Fact sheets on anticancer drugs. [Bethesda, Md.?: National Cancer Institute, 1994.
Znajdź pełny tekst źródłaSotiris, Missailidis, red. Anticancer therapeutics. Chichester: John Wiley & Sons, 2008.
Znajdź pełny tekst źródła1964-, Spencer Peter, i Holt Walter, red. Anticancer drugs: Design, delivery and pharmacology. Hauppauge, NY: Nova Science Publishers, 2009.
Znajdź pełny tekst źródłaSaeidnia, Soodabeh. New Approaches to Natural Anticancer Drugs. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-14027-8.
Pełny tekst źródłaHacker, Miles P., John S. Lazo i Thomas R. Tritton, red. Organ Directed Toxicities of Anticancer Drugs. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4613-2023-4.
Pełny tekst źródłaHildebrand, Jerzy, red. Neurological Adverse Reactions to Anticancer Drugs. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-76142-3.
Pełny tekst źródłaCzęści książek na temat "Anticancer drugs"
Schacter, Lee, Marcel Rozencweig, Claude Nicaise, Renzo Canetta, Susan Kelley i Laurie Smaldone. "Anticancer Drugs". W Early Phase Drug Evaluation in Man, 644–54. London: Macmillan Education UK, 1990. http://dx.doi.org/10.1007/978-1-349-10705-6_49.
Pełny tekst źródłaSchwab, Matthias, Elke Schaeffeler i Hiltrud Brauch. "Anticancer Drugs". W Metabolism of Drugs and Other Xenobiotics, 365–78. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2012. http://dx.doi.org/10.1002/9783527630905.ch13.
Pełny tekst źródłaIsnard-Bagnis, Corinne, Vincent Launay-Vacher, Svetlana Karie i Gilbert Deray. "Anticancer drugs". W Clinical Nephrotoxins, 511–35. Boston, MA: Springer US, 2008. http://dx.doi.org/10.1007/978-0-387-84843-3_22.
Pełny tekst źródłaZhao, Le, Zengyi Shao i Jacqueline V. Shanks. "Anticancer Drugs". W Industrial Biotechnology, 237–69. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2016. http://dx.doi.org/10.1002/9783527807833.ch8.
Pełny tekst źródłaGanguly, A. K., i Sesha Sridevi Alluri. "Anticancer Drugs". W Medicinal Chemistry, 89–101. Boca Raton: CRC Press, 2021. http://dx.doi.org/10.1201/9781003182573-4.
Pełny tekst źródłaIsnard-Bagnis, Corinne, i Gilbert Deray. "Anticancer drugs". W Clinical Nephrotoxins, 353–72. Dordrecht: Springer Netherlands, 2003. http://dx.doi.org/10.1007/1-4020-2586-6_18.
Pełny tekst źródłaCateni, Francesca, i Marina Zacchigna. "PEG–Anticancer Drugs". W Macromolecular Anticancer Therapeutics, 221–63. New York, NY: Springer New York, 2009. http://dx.doi.org/10.1007/978-1-4419-0507-9_6.
Pełny tekst źródłaKim, Kyu-Won, Jae Kyung Roh, Hee-Jun Wee i Chan Kim. "Immunotherapeutic Anticancer Drugs and Other Miscellaneous Anticancer Drugs". W Cancer Drug Discovery, 135–53. Dordrecht: Springer Netherlands, 2016. http://dx.doi.org/10.1007/978-94-024-0844-7_7.
Pełny tekst źródłaKim, Kyu-Won, Jae Kyung Roh, Hee-Jun Wee i Chan Kim. "Alkylating Anticancer Drugs". W Cancer Drug Discovery, 71–94. Dordrecht: Springer Netherlands, 2016. http://dx.doi.org/10.1007/978-94-024-0844-7_4.
Pełny tekst źródłaKim, Kyu-Won, Jae Kyung Roh, Hee-Jun Wee i Chan Kim. "Antimetabolic Anticancer Drugs". W Cancer Drug Discovery, 95–112. Dordrecht: Springer Netherlands, 2016. http://dx.doi.org/10.1007/978-94-024-0844-7_5.
Pełny tekst źródłaStreszczenia konferencji na temat "Anticancer drugs"
Ma, Liang, Jeremy Barker, Changchun Zhou, Biaoyang Lin i Wei Li. "A Perfused Two-Chamber System for Anticancer Drug Screening". W ASME 2010 International Manufacturing Science and Engineering Conference. ASMEDC, 2010. http://dx.doi.org/10.1115/msec2010-34326.
Pełny tekst źródłaSchiestl, Robert H., Michael Davoren i Yelena Rivina. "Abstract 1793: Novel radiation mitigators and anticancer drugs". W Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-1793.
Pełny tekst źródłaSettleman, Jeffrey E. "Abstract CN06-04: Reversible tolerance to anticancer drugs." W Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-cn06-04.
Pełny tekst źródłaSchiestl, Robert H., Yelena Rivina i Michael Davoren. "Abstract 3729: Novel radiation mitigators and anticancer drugs". W Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-3729.
Pełny tekst źródłaZhukovets, T. A., M. А. Khancheuski, I. V. Koktysh, E. I. Kvasyuk i A. G. Sysa. "ANTIOXIDANT EFFECTS OF EMOXYPINE AS ADJUVANT OF ANTI-CANCER DRUGS". W SAKHAROV READINGS 2021: ENVIRONMENTAL PROBLEMS OF THE XXI CENTURY. International Sakharov Environmental Institute of Belarusian State University, 2021. http://dx.doi.org/10.46646/sakh-2021-2-52-55.
Pełny tekst źródłaCao, Tingying, Xiangdong Gao i Yueqing Gu. "Biodegradable polylactide microspheres containing anticancer drugs used as injectable drug delivery system". W 2007 IEEE/ICME International Conference on Complex Medical Engineering. IEEE, 2007. http://dx.doi.org/10.1109/iccme.2007.4381726.
Pełny tekst źródłaNikkhah, Mehdi, Jeannine S. Strobl i Masoud Agah. "Study the Effect of Anticancer Drugs on Human Breast Cancer Cells Using Three Dimensional Silicon Microstructures". W ASME 2008 International Mechanical Engineering Congress and Exposition. ASMEDC, 2008. http://dx.doi.org/10.1115/imece2008-66680.
Pełny tekst źródłaJ., Alex Mathew, i Nixon Raj N. "Insilico Docking Studies on Anticancer Drugs for Breast Cancer". W 2009 International Association of Computer Science and Information Technology - Spring Conference. IEEE, 2009. http://dx.doi.org/10.1109/iacsit-sc.2009.12.
Pełny tekst źródłaShrestha, Gajendra, Michael Xiao, Richard Robison, Larry L. St Clair i Kim O'Neill. "Abstract 3220: Lichen derived polyphenols as potential anticancer drugs". W Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-3220.
Pełny tekst źródłaRibeiro, Tatiane. "23 Evidence-based medicine challenges in new anticancer drugs". W EBM Live Abstracts, July 2019, Oxford, UK. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/bmjebm-2019-ebmlive.104.
Pełny tekst źródłaRaporty organizacyjne na temat "Anticancer drugs"
Howard, David, Peter Bach, Ernst Berndt i Rena Conti. Pricing in the Market for Anticancer Drugs. Cambridge, MA: National Bureau of Economic Research, styczeń 2015. http://dx.doi.org/10.3386/w20867.
Pełny tekst źródłaZhang, Jian-Ting. Molecular Study of Interactions between P-Glycoprotein and Anticancer Drugs. Fort Belvoir, VA: Defense Technical Information Center, sierpień 1995. http://dx.doi.org/10.21236/ada300162.
Pełny tekst źródłaBiswas, Kaustav, i Samuel J. Danishefsky. Synthesis of Epothilone Analogs: Toward the Development of Potent Anticancer Drugs. Fort Belvoir, VA: Defense Technical Information Center, sierpień 2002. http://dx.doi.org/10.21236/ada409475.
Pełny tekst źródłaInoue, Takashi, i Mamoru Narukawa. Anti-tumor efficacy of anti-PD-1/PD-L1 antibodies in combination with other anticancer drugs in solid tumors: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, październik 2022. http://dx.doi.org/10.37766/inplasy2022.10.0004.
Pełny tekst źródłaFeltmate, Colleen. Application of Nanotechnology in the Targeted Release of Anticancer Drugs in Ovarian Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, grudzień 2007. http://dx.doi.org/10.21236/ada486569.
Pełny tekst źródłaFeltmate, Colleen. Application of Nanotechnology in the Targeted Release of Anticancer Drugs in Ovarian Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, grudzień 2006. http://dx.doi.org/10.21236/ada481424.
Pełny tekst źródłaBeerman, Terry A. Discovery of DNA Binding Anticancer Drugs That Target Oncogenic Transcription Factors Associated With Human Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, październik 2001. http://dx.doi.org/10.21236/ada403322.
Pełny tekst źródłaVenedicto, Melissa, i Cheng-Yu Lai. Facilitated Release of Doxorubicin from Biodegradable Mesoporous Silica Nanoparticles. Florida International University, październik 2021. http://dx.doi.org/10.25148/mmeurs.009774.
Pełny tekst źródłaMacedo, Luciana, i Linda Malkas. The Human Breast Cancer DNA Synthesome Can Serve as a Novel In Vitro Model System for Studying the Mechanism of Action of Anticancer Drugs. Fort Belvoir, VA: Defense Technical Information Center, lipiec 2000. http://dx.doi.org/10.21236/ada393926.
Pełny tekst źródłaJiang, Haiyan. The Human Breast Cancer Cell DNA Synthesome Can Serve as a Novel in Vitro Model System for Studying the Mechanism of Action of Anticancer Drugs. Fort Belvoir, VA: Defense Technical Information Center, lipiec 1999. http://dx.doi.org/10.21236/ada384124.
Pełny tekst źródła